Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V K Shivane

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Postgraduate Medicine|October 10, 2020
Type 2 diabetic Asian Indians and COVID-19: Lessons learnt so far from the ongoing pandemicV K Shivane, A R Lila, T R Bandgar
Journal of Postgraduate Medicine|August 15, 2014
Pioglitazone: Hype and hopeS S Jadhav, V K Shivane, A R Lila, et al.
Diabetes, Obesity & Metabolism|January 17, 2013
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneE J Rhee, W Y Lee, K W Min, et al.
Diabetes, Obesity & Metabolism|November 23, 2012
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetesS J Yang, K W Min, S K Gupta, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Postgraduate Medicine|October 10, 2020
Type 2 diabetic Asian Indians and COVID-19: Lessons learnt so far from the ongoing pandemicV K Shivane, A R Lila, T R Bandgar
Journal of Postgraduate Medicine|August 15, 2014
Pioglitazone: Hype and hopeS S Jadhav, V K Shivane, A R Lila, et al.
Diabetes, Obesity & Metabolism|January 17, 2013
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneE J Rhee, W Y Lee, K W Min, et al.
Diabetes, Obesity & Metabolism|November 23, 2012
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetesS J Yang, K W Min, S K Gupta, et al.
Pageof 1